Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study

OBJECTIVES: To evaluate, in a multicentric Italian cohort of axial spondyloarthritis (axSpA) patients on Secukinumab (SEC) followed for 24 months: (1) the long-term effectiveness and safety of SEC; (2) the drug retention rate and low disease activity (LDA) measured as Bath Ankylosing Spondylitis Dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramonda, Roberta, Lorenzin, Mariagrazia, Sole Chimenti, Maria, D’Angelo, Salvatore, Marchesoni, Antonio, Salvarani, Carlo, Lubrano, Ennio, Costa, Luisa, Dal Bosco, Ylenia, Fracassi, Elena, Ortolan, Augusta, Ferraioli, Mario, Carriero, Antonio, Visalli, Elisa, Bixio, Riccardo, Desiati, Francesca, Bergamini, Alberto, Pedrollo, Elisa, Doria, Andrea, Foti, Rosario, Carletto, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058366/
https://www.ncbi.nlm.nih.gov/pubmed/35510168
http://dx.doi.org/10.1177/1759720X221090310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058366/
https://www.ncbi.nlm.nih.gov/pubmed/35510168
http://dx.doi.org/10.1177/1759720X221090310

Ejemplares similares